StockNews.com Begins Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

NASDAQ:BLPH opened at $0.04 on Friday. The firm has a market capitalization of $440,388.00, a price-to-earnings ratio of -0.04 and a beta of 0.70. The business’s 50-day moving average price is $0.04 and its two-hundred day moving average price is $0.05. Bellerophon Therapeutics has a 1-year low of $0.03 and a 1-year high of $0.42.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.